Company: VRCA
Filing Date: 2025-12-15
Form Type: S-3
Source: 0001193125-25-319225
Chunk: 5

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-15
Form: S-3
Chunk 5
---
 (the “Exchange Act”), meaning that the market value of our shares held by non-affiliates is less than
$700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year for which audited financial statements are available as of
the determination date and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. If investors consider our common stock less attractive as a result of
our election to use the scaled-back disclosure permitted for smaller reporting companies, there may be a less active trading market for our common stock and our share price may be more volatile.

Additionally, as a non-accelerated filer, we may continue to take advantage of the exception from
compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended.

Corporate Background

We were incorporated under the laws of the State of Delaware on July 3, 2013. Our principal executive offices are located at 44 West Gay
Street, Suite 400, West Chester, PA 19380 and our telephone number is

1

(484) 453-3300. Our website address is www.verrica.com. The information contained on, or accessible through, our website is not incorporated by
reference into this prospectus, and you should not consider any information contained in, or that can be accessed through, our website as part of this prospectus.

Private Placement

On November 23,
2025, we entered into the Purchase Agreements with the selling stockholders named herein, pursuant to which we agreed to sell and issue to the Purchasers in a private placement transaction (the “Private Placement”) an aggregate of (i)
6,499,826 shares of our common stock, (ii) with respect to certain Purchasers, pre-funded warrants